<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290900</url>
  </required_header>
  <id_info>
    <org_study_id>D4280C00007</org_study_id>
    <nct_id>NCT01290900</nct_id>
  </id_info>
  <brief_title>A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose study in healthy male volunteers to investigate the effect of high
      doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT
      interval
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG will be performed pre-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 30 min after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 60 min after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 90 min after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 2 hour after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 3 hour after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 4 hour after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 6 hour after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 8 hour after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 12 hour after starting dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).</measure>
    <time_frame>12-lead dECG at 24 hour after starting dosing.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG will be performed pre-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 30 min after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 60 min after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 90 min after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 2 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 3 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 4 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 6 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 8 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 12 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).</measure>
    <time_frame>12-lead dECG at 24 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken pre-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 30 min after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 60 min after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 75 min after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 90 min after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 2 hour after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 3 hour after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 4 hour after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 6 hour after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 8 hour after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 12 hour after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 18 hour after starting dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.</measure>
    <time_frame>Blood samples will be taken at 24 hour after starting dosing.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>CXL104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 mg NXL104 + 1500 mg Ceftaroline (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAZ104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin 400mg (1 tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Infusion (saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXL104</intervention_name>
    <description>IV Solution</description>
    <arm_group_label>CXL104</arm_group_label>
    <arm_group_label>CAZ104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftaroline</intervention_name>
    <description>IV Solution</description>
    <arm_group_label>CXL104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Infusion</intervention_name>
    <description>IV Saline</description>
    <arm_group_label>CAZ104</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>IV Solution</description>
    <arm_group_label>CAZ104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Tablet (1)</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed informed consent prior to any study specific procedures

          -  Healthy male volunteers aged 18 to 45 years (inclusive) with suitable veins for
             cannulation or repeated venepuncture

          -  Have a body mass index (BMI) between 19 and 30 kg/m2 and a body weight between 60 and
             100 kg

          -  Be a non-smoker or ex-smoker who has stopped smoking (or using other nicotine
             products) for more than 3 months prior to the start of the study

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the volunteer at risk because of participation in the
             study, or influence the results or the volunteer's ability to participate in the study

          -  Any clinically significant abnormalities in physical examination, clinical chemistry,
             haematology or urinalysis results as judged by the Investigator

          -  Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:
             Systolic blood pressure (SBP) greater than 140 mmHg, Diastolic blood pressure (DBP)
             greater than 90 mmHg, Heart rate less than 40 or greater than 85 beats per minute - at
             Visit 1

          -  Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG that may interfere with the interpretation of QTc interval changes. This includes
             volunteers with any of the following: Clinically significant PR (PQ) interval
             prolongation, Intermittent second or third degree AV block (Mobitz II type 1,
             Wenchebach during sleep is not disqualifying), Incomplete, full or intermittent bundle
             branch block (QRS less than 110 ms with normal QRS and T wave morphology is acceptable
             if there is no evidence of left ventricular hypertrophy), Abnormal T wave morphology,
             particularly in the protocol defined primary lead
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Newell, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <name_title>Paul Newell / Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>NXL104</keyword>
  <keyword>CAZ104</keyword>
  <keyword>Ceftazidime</keyword>
  <keyword>CXL104</keyword>
  <keyword>Ceftaroline</keyword>
  <keyword>Healthy Male Volunteers</keyword>
  <keyword>Phase 1</keyword>
  <keyword>OT</keyword>
  <keyword>Single Dose Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

